Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: Market Lessons From The Contrave Complete Response Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on financial transactions by Seattle Genetics, Nektar, Pharmasset and Pacira.

You may also be interested in...

Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts